CliffBio
small molecule

EMTRICITABINE

EMTRICITABINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMTRICITABINE
Active ingredientEMTRICITABINE
Strength200MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EMTRICITABINE patent cliff — loss of exclusivity — | CliffBio